JP2010524476A5 - ＴＮＦスーパーファミリー受容体についてのスプライススイッチオリゴマー、それを含有する組成物、可溶性形態のＴＮＦ−α受容体２、およびそれらの使用方法 - Google Patents
ＴＮＦスーパーファミリー受容体についてのスプライススイッチオリゴマー、それを含有する組成物、可溶性形態のＴＮＦ−α受容体２、およびそれらの使用方法 Download PDFInfo
- Publication number
- JP2010524476A5 JP2010524476A5 JP2010504466A JP2010504466A JP2010524476A5 JP 2010524476 A5 JP2010524476 A5 JP 2010524476A5 JP 2010504466 A JP2010504466 A JP 2010504466A JP 2010504466 A JP2010504466 A JP 2010504466A JP 2010524476 A5 JP2010524476 A5 JP 2010524476A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- tnf
- oligomer
- oligomer according
- soluble form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100009534 TNF Human genes 0.000 title claims 8
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 6
- 210000004027 cells Anatomy 0.000 claims 4
- 210000004962 mammalian cells Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 101710040537 TNF Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (10)
- １０〜１６核酸塩基長のオリゴマーであって、ＣＡＡＴＣＡＧＴＣＣ（配列番号１４３）、ＴＣＣＴＡＧＡＡＡＧ（配列番号１５９）、およびＴＴＴＣＡＣＣＴＧＧ（配列番号１７５）からなる群より選択される核酸塩基配列を含むとともに、前記オリゴマーはその全体にわたり２’−デオキシ−およびロックト核酸（ＬＮＡ）のホスホロチオエート結合による交互ヌクレオシドからなり、かつ、５’末端のヌクレオシドがＬＮＡであるオリゴマー。
- ＬＮＡ単位は２’Ｏ−４’−（メチレン）−二環式リボヌクレオシド単位である請求項１に記載のオリゴマー。
- 配列番号１３０，１３７，１３９，１４３，１４６，１５３，１５５，１５９，１６２，１６９，１７１、および１７５からなる群より選択される配列を有する請求項１または２に記載のオリゴマー。
- 請求項１〜３のいずれか一項に記載のオリゴマーおよび医薬的に許容される担体を含有する組成物。
- ＴＮＦ−α受容体２（ＴＮＦＲ２）を発現する哺乳動物細胞において前記受容体のプレｍＲＮＡのスプライシングを変化させる方法であって、請求項１〜３のいずれか一項に記載のオリゴマーまたは請求項４に記載の組成物を前記細胞に投与する工程からなる方法。
- ＴＮＦ−α受容体２（ＴＮＦＲ２）を発現する哺乳動物細胞において前記受容体の可溶性形態を調製する方法であって、請求項１〜３のいずれか一項に記載のオリゴマーまたは請求項４に記載の組成物を前記細胞に投与する工程、および任意にＴＮＦ−α受容体２の可溶性形態を前記細胞から単離または精製する工程からなる方法。
- ＴＮＦ−α受容体２（ＴＮＦＲ２）を発現する哺乳動物細胞において前記受容体の可溶性形態の発現を高める方法であって、請求項１〜３のいずれか一項に記載のオリゴマーまたは請求項４に記載の組成物を前記細胞に投与する工程からなるとともに、インビトロまたはインビボで実施される方法。
- 炎症性疾患または状態の治療用薬剤を製造するための、請求項１〜３のいずれか一項に記載のオリゴマーまたは請求項４に記載の組成物の使用方法。
- 請求項６に記載の方法に従って製造された、単離または精製された可溶性形態のＴＮＦ−α受容体２。
- 炎症性疾患または状態の治療用薬剤を製造するための、請求項６に記載の方法に従って製造された、単離または精製された可溶性形態のＴＮＦ−α受容体２の使用方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/010556 WO2008051306A1 (en) | 2006-10-20 | 2007-05-01 | Soluble tnf receptors and their use in treatment of disease |
| US11/799,117 US7785834B2 (en) | 2005-11-10 | 2007-05-01 | Soluble TNF receptors and their use in treatment of disease |
| PCT/EP2007/061211 WO2008131807A2 (en) | 2007-05-01 | 2007-10-19 | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222417A Division JP2014050400A (ja) | 2007-05-01 | 2013-10-25 | Ｔｎｆスーパーファミリー受容体についてのスプライススイッチオリゴマー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524476A JP2010524476A (ja) | 2010-07-22 |
| JP2010524476A5 true JP2010524476A5 (ja) | 2010-12-02 |
Family
ID=39929868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504466A Pending JP2010524476A (ja) | 2007-05-01 | 2007-10-19 | Ｔｎｆスーパーファミリー受容体についてのスプライススイッチオリゴマーおよび疾患の治療におけるそれらの使用方法 |
| JP2013222417A Pending JP2014050400A (ja) | 2007-05-01 | 2013-10-25 | Ｔｎｆスーパーファミリー受容体についてのスプライススイッチオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222417A Pending JP2014050400A (ja) | 2007-05-01 | 2013-10-25 | Ｔｎｆスーパーファミリー受容体についてのスプライススイッチオリゴマー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120142759A1 (ja) |
| EP (1) | EP2147103B1 (ja) |
| JP (2) | JP2010524476A (ja) |
| KR (5) | KR20180082646A (ja) |
| CN (2) | CN104278033A (ja) |
| AU (6) | AU2007352163A1 (ja) |
| CA (4) | CA2684724A1 (ja) |
| HK (2) | HK1150850A1 (ja) |
| MX (2) | MX2009011856A (ja) |
| WO (1) | WO2008131807A2 (ja) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001257526B2 (en) | 2000-05-04 | 2007-07-19 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| EP1713332A4 (en) | 2004-01-23 | 2010-08-18 | Avi Biopharma Inc | ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US7785834B2 (en) | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
| EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
| WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| WO2011159836A2 (en) | 2010-06-15 | 2011-12-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| US10273474B2 (en) | 2012-03-30 | 2019-04-30 | Washington University | Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| WO2014059341A2 (en) * | 2012-10-12 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| CN104955952A (zh) | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna寡核苷酸碳水化合物缀合物 |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| WO2017067970A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
| CN109328236B (zh) | 2016-06-17 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 体外肾毒性筛选测定法 |
| WO2017216325A1 (en) | 2016-06-17 | 2017-12-21 | F. Hoffmann-La Roche Ag | In vitro nephrotoxicity screening assay |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| EP3339408B1 (en) * | 2016-12-22 | 2020-01-29 | The Procter & Gamble Company | Fabric softener composition having improved dispensing properties |
| SG11202001103QA (en) * | 2017-08-11 | 2020-03-30 | Agency Science Tech & Res | Method for screening splicing variants or events |
| KR20200104347A (ko) | 2017-12-22 | 2020-09-03 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 |
| WO2019122277A1 (en) | 2017-12-22 | 2019-06-27 | Roche Innovation Center Copenhagen A/S | Novel thiophosphoramidites |
| EP3728592B1 (en) | 2017-12-22 | 2024-05-29 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorodithioate internucleoside linkage |
| EP3620519A1 (en) | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
| EP3914232A1 (en) | 2019-01-25 | 2021-12-01 | F. Hoffmann-La Roche AG | Lipid vesicle for oral drug delivery |
| KR102470669B1 (ko) * | 2022-06-03 | 2022-11-25 | 충남대학교 산학협력단 | 스플라이싱-스위치 올리고뉴클레오티드를 유효성분으로 포함하는 폴리프로모 1 유전자의 스플라이싱 조절용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410324B1 (en) | 2001-04-27 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of tumor necrosis factor receptor 2 expression |
| US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
| CA2477014A1 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina) |
| EP1951872A2 (en) * | 2005-11-10 | 2008-08-06 | The University of North Carolina at Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| EP2089521A1 (en) * | 2006-02-08 | 2009-08-19 | Ercole Biotech, Inc. | Soluble tnf receptors and their use in treatment of disease |
| US20090264353A1 (en) * | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
-
2007
- 2007-10-19 CN CN201410244615.9A patent/CN104278033A/zh active Pending
- 2007-10-19 MX MX2009011856A patent/MX2009011856A/es active IP Right Grant
- 2007-10-19 KR KR1020187020209A patent/KR20180082646A/ko not_active Application Discontinuation
- 2007-10-19 JP JP2010504466A patent/JP2010524476A/ja active Pending
- 2007-10-19 CA CA002684724A patent/CA2684724A1/en not_active Abandoned
- 2007-10-19 CA CA3072221A patent/CA3072221A1/en not_active Abandoned
- 2007-10-19 KR KR1020157033784A patent/KR101738655B1/ko active IP Right Grant
- 2007-10-19 AU AU2007352163A patent/AU2007352163A1/en not_active Abandoned
- 2007-10-19 US US12/598,453 patent/US20120142759A1/en not_active Abandoned
- 2007-10-19 MX MX2012008375A patent/MX346434B/es unknown
- 2007-10-19 KR KR1020177013046A patent/KR20170056032A/ko active Application Filing
- 2007-10-19 KR KR1020157006381A patent/KR20150036814A/ko not_active Application Discontinuation
- 2007-10-19 CA CA3165250A patent/CA3165250A1/en active Pending
- 2007-10-19 CA CA2991580A patent/CA2991580A1/en not_active Abandoned
- 2007-10-19 EP EP07821575.3A patent/EP2147103B1/en active Active
- 2007-10-19 WO PCT/EP2007/061211 patent/WO2008131807A2/en active Application Filing
- 2007-10-19 CN CN200780053595.5A patent/CN101889086B/zh active Active
- 2007-10-19 KR KR1020097025067A patent/KR101531934B1/ko active IP Right Grant
-
2011
- 2011-05-16 HK HK11104796.5A patent/HK1150850A1/xx not_active IP Right Cessation
-
2013
- 2013-10-25 JP JP2013222417A patent/JP2014050400A/ja active Pending
-
2014
- 2014-06-13 AU AU2014203220A patent/AU2014203220A1/en not_active Abandoned
-
2015
- 2015-06-15 HK HK15105622.8A patent/HK1205184A1/xx unknown
-
2016
- 2016-05-17 AU AU2016203220A patent/AU2016203220A1/en not_active Abandoned
-
2018
- 2018-01-17 AU AU2018200382A patent/AU2018200382A1/en not_active Abandoned
-
2019
- 2019-07-26 AU AU2019208249A patent/AU2019208249A1/en not_active Abandoned
-
2021
- 2021-06-29 AU AU2021204434A patent/AU2021204434A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524476A5 (ja) | ＴＮＦスーパーファミリー受容体についてのスプライススイッチオリゴマー、それを含有する組成物、可溶性形態のＴＮＦ−α受容体２、およびそれらの使用方法 | |
| JP7002603B2 (ja) | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド | |
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| KR102473431B1 (ko) | 안티센스 핵산 | |
| KR102071729B1 (ko) | 안티센스 핵산 | |
| AU2015252841B2 (en) | Compositions and methods for modulating growth hormone receptor expression | |
| WO2012053741A2 (ko) | Rna 간섭을 유도하는 핵산 분자 및 그 용도 | |
| JP2011504362A5 (ja) | ||
| CN107073137A (zh) | 减少内含子保留 | |
| US11667918B2 (en) | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA | |
| CN106459955A (zh) | 反义核酸 | |
| JP2016513976A5 (ja) | ||
| JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| AU2018350693B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
| CN116113424A (zh) | 快速疫苗平台 | |
| CN110832077A (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| CA3079413A1 (en) | Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1 | |
| EP2931893A1 (en) | T-cell modulation by exon skipping | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| EP3873920A1 (en) | Antisense oligonucleotides targeting tia1 | |
| TW202019944A (zh) | 含有三硫代磷酸酯核苷間連接之寡核苷酸 | |
| TW201828953A (zh) | 亞伯氏症候群治療藥 | |
| NZ764037A (en) | Compositions and methods for modulating growth hormone receptor expression |